Long-Term Study of IGIV, 10% in Alzheimer´s Disease
Terminated
Baxalta now part of Shire
Phase 3
2012-11-29
The purpose of this long-term study is to provide additional evidence of safety and efficacy
of IGIV, 10% treatment in participants with Alzheimer´s Disease who have completed the Phase
3 Baxter precursor study 160701. All participants will receive IGIV, 10% at either 0.2 g/kg
or 0.4 g/kg body weight depending on their treatment assignment in Baxter study 160701.
Participants and investigators will be blinded to dose unless otherwise notified by the
sponsor.
Long-Term Study of IGIV, 10% in Alzheimer´s Disease
Terminated
Baxalta US Inc.
Phase 3
2012-11-29
The purpose of this long-term study is to provide additional evidence of safety and efficacy
of IGIV, 10% treatment in participants with Alzheimer´s Disease who have completed the Phase
3 Baxter precursor study 160701. All participants will receive IGIV, 10% at either 0.2 g/kg
or 0.4 g/kg body weight depending on their treatment assignment in Baxter study 160701.
Participants and investigators will be blinded to dose unless otherwise notified by the
sponsor.
ASIS Corporation (ASIS) has developed the only automatic injection system for delivery of
injectable products to it's optimum/right spot, just outside of the fascia, which exists
subdermally (between the skin and muscle). Bloodless basically implies longer lasting
medicinal effects, and minimal side effects - advantages that reflect the NIH mission of
enhancing health, lengthening life, and reducing the burdens of illness and disability. ASIS
device is stabilized on the surface of the skin with negative pressure and emits an
electrical current to create a bloodless cavity subdermally. ASIS device correctly,
automatically, and consistently delivers therapeutic agents, yet requiring little skill of a
practitioner - providing the steady and safe infusion into subdermal bloodless space of
virtually any injectable product in addition to Botox, including GAMMAGARD LIQUID, Enbrel,
Insulin, and Fillers, etc. According to the FDA, "This innovation will have major impact on
the healthcare industry."
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
